The introduction of immune-checkpoint inhibitors (ICIs) targeting programmed death protein (PD-1) and its ligand (PD-L1) or cytotoxic lymphocyte antigen 4 (CTLA-4) has improved the overall survival of advanced NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.